Abstract 1672P
Background
Waiting involves staying in a place until an expected event occurs. From diagnosis to follow-up and treatment, cancer patients (pts) often endure waiting. Understanding their emotions during this time is crucial. Few studies have explored the experiences and emotions of cancer pts in the waiting room (WR).
Methods
An anonymous 12-item online questionnaire was distributed to cancer pts in our center's WR. The questionnaire was divided into 3 sections including clinical and socio-demographic information, time spent in the WR, and pts considerations. The aim of this study was to investigate cancer pts’ emotions and behaviors in the WR.
Results
160 pts completed the questionnaire (48% women, 52% men). The most common age groups were 51-65 years old (37%) and 66-80 years old (41%). The majority of pts are unemployed (58.5%). About half of interviewed pts undergo infusion therapies and/or visit 1-2 times monthly. When asked to describe the wait duration, approximately half found it long (32%) or too long (17%). Pts spend this period on mobile phones (47%), watching TV (21%), reading or listening to music (16%), and conversing with others (11%). Both positive (49% calm, 7.5% hopeful, 5% emotional involvement) and negative (26% boredom, 21% anxiety, 6% sadness, 5% anger, 1% apathy) emotions were experienced. The multiple logistic regression model confirms the independent predictor role for a negative emotional status in the WR of a perceived long or too long waiting period (OR=4.0, p<0.001) and the independent role of protector of male gender (OR=0.4, p0.008). A trend of significance emerged for employment (OR=0.4, p0.052) and engaging in active behaviors (OR=0.4, p0.058) as protective factors. When asked how to improve the quality of time in the WR, 38% suggested live entertainment (music, readings, and cancer information), 26% preferred access to newspapers and magazines. The most requested topics are treatment news (51%), diet (46%), and physical activity (27%).
Conclusions
For cancer pts the waiting can be a meaningful experience. Many pts find the wait long, boring, and anxiety-provoking. Our experience suggests how active and externalizing behaviors are less linked to negative emotions and interactive activities could improve the quality of time spent in the WR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11